|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||43.90 - 45.15|
|52-week range||37.59 - 85.58|
|Beta (5Y monthly)||0.61|
|PE ratio (TTM)||N/A|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||73.00|
Today is shaping up negative for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders, with the analysts...
WATERTOWN, Mass., November 22, 2022--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November:
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?